IN DEVELOPMENT: CB003

Cubed's first compound in development: a stacked multiple-API formula

Illustration

Psilocybin | 20 mg

Derived from psilocybe mushrooms

Illustration

Mescaline | 100 mg

Mescaline is derived from cacti:San Pedro, Peyote & Peruvian Toruch

Illustration

DMT/MAO | 5 mg

The two active ingredients in Ayahuasca

Our Path

We will partner with universities to conduct clinical trials then produce our proprietary drug compounds and manufacture for our partners.

Our process

1

Build Facility

1

2

Receive Licenses

2

3

Grow & Import Entheogen

3

4

Extract & Purify

4

5

Produce pharma medications

5

TACKLING THE MENTAL HEALTH CRISIS

A Vast Global Potential Market already used for centuries for:

DEPRESSION – ADDICTION - POST-TRAUMATIC STRESS DISORDER (PTSD)Growing psychedelic research & acceptance for treating depression FDA is fast-tracking Psilocybin as a ”Breakthrough Treatment” COVID-19 has increased global mental health awareness
ACTIVE GOVERNMENTAL RESPONSERising Health care costs force governments to look for economic therapiesCannabis legalization opened new regulations, infrastructure & reduces stigmaGovernments leading the charge: U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) invested $27 million in psychedelicsSource: https://thedalesreport.com/psychedelics/what-the-u-s-militarys-27-million-investment-in-novel-psychedelic-type-drugs-could-mean-for-veterans